Thank you for taking a moment to provide feedback on your experience at the Denali ALS Focus Group. We will use your feedback to create future programs and inform our clinical trial design.
Section 1 - Meeting Feedback

Question Title

* 1. Please rate the following statements on a scale of 1 to 5:

  1. Strongly Disagree 2. Disagree 3. Neutral 4. Agree 5. Strongly Agree
I was able to engage openly with moderators and other attendees.
I felt comfortable sharing my experience and articulating my questions, needs, and concerns.
I felt my voice was heard.
I have a better understanding of Denali Therapeutics and the company’s mission.
I learned something valuable during this meeting.

Question Title

* 2. In your opinion, what was the most important information or feedback shared by attendees that Denali Therapeutics should take away from this Focus Group?

Question Title

* 3. Please rate your experience with the following (by marking one score for each element):

  Poor Average Above Average
Meeting Format
Registration and contracting process
Participant instructions
Meeting content clarity
Overall satisfaction with meeting

Question Title

* 4. How would you describe the 90-minute duration of the Focus Group?

Question Title

* 5. How would you describe the amount of content covered during the Focus Group?

Question Title

* 6. Please share any feedback on how we can improve future focus groups.

Section 2 – Supplemental Discussion Questions

Question Title

* 7. During the Focus Group, we shared information about how the investigational DNL343 therapy works (i.e., the mechanism of action, MOA).

Please see the visual below for reference:

  Yes No
Was it helpful to learn about the MOA for a potential ALS therapy like DNL343?
Did the information and overview provided help you have a good understanding of the MOA for DNL343?
Was the MOA description clear for the purposes of the Focus Group discussion?

Question Title

Image

Question Title

Image

Question Title

* 8. How do you feel about the length of the Denali DNL343 clinical study (48 weeks) and long-term extension phase (52 weeks minimum to 78 weeks maximum)?

Question Title

* 9. What additional clinical assessments of disease progression would be meaningful to include in future clinical trials?

Question Title

* 10. What channels of communication are most effective for you to stay informed on ALS clinical trials and therapy development in general? (E.g., in-person or virtual conferences, social media such as Facebook or Instagram)

Question Title

* 11. What types of information would prompt you to consider participation in a clinical study for you or your loved one?

Question Title

* 12. Would you want to be provided with information to help your physician (neurologist) learn more about clinical trials or ALS potential treatments in general?

Question Title

* 13. If so, what information do you feel is most important to provide?

Question Title

* 14. We discussed the need for increased awareness about research, ongoing clinical trials, and FDA-approved therapies for ALS within rural and underserved communities. What are your thoughts or suggestions as to how to reach these specific populations?

Question Title

* 15. In this Focus Group we covered clinical study inclusion and exclusion criteria, assessments and measurements, and study communication best practices. What are other topics are important for sponsors like Denali to get community feedback on?

Question Title

* 16. Do you have any additional questions or thoughts you were not able to share during the discussion? If so, please share them below.

Thank you again for your feedback.
Confidential. For participant completion only. Please do not distribute or share this survey.

T